AT506953T

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Abstract

Use of an effective amount of a compound 2,4-pirimidindiamínico according to structural formula (Id) for preparing a medicament for inhibiting proliferation of a cancer cell: Structural formula to (Id) including salts, hydrates, solvates and N-oxides, wherein: Z1 is selected from N and CH; Z2 is selected from NH, O, S and S (O) 2; R16 is selected from hydrogen and methyl; R19 is selected from the group consisting of hydrogen, alkyl (C1-C8), methyl and Rd; R20 is selected from the group consisting of hydrogen, alkyl (C1-C8), methyl and Rd; where each Rd is independently selected from monohydroxy (C1-C8) and dihydroxy (C1C8); R24 is selected from hydrogen and methyl; R41 is selected from alkyl (C1-C8), methyl; (C1-C8), methoxy, halo, chloro, trifluoromethyl and -CH2OH; R42 is selected from hydrogen, (C1-C8), methyl, hydroxy, (C1-C8), methoxy, halo, chloro, trifluoromethyl, trifluoromethoxy, -OCH2C (O) NHRa, and ** ** ** Formula Formula ** and R43 is selected from hydrogen, (C1-C8), methyl, hydroxy, (C1-C8), methoxy, halo, chloro, trifluoromethyl, trifluoromethoxy, -OCH2C (O) NHRa, -OCH2C (O) ORa ** Formula Formula ** and ** ** where each R12 is independently selected from the group consisting of alkyl (C1-C8) alkyl, aryl, - ORa, -NRcRc, -C (O) Ra, -C (O) ORa and -C (O) NRcRc; each R is independently selected from the group consisting of hydrogen, alkyl (C1-C8), (C3-C8), cycloalkyl (C3-C8) alkyl (C1-C4) alkyl, phenyl and benzyl; and each Rc is independently selected from the group consisting of hydrogen, (C1-C8) and cycloalkyl (C3-C8), or alternatively, may take two Rc together with the nitrogen atom to which they are attached to form a saturated ring 5-7 membered optionally includes an additional 1-2 heteroaromatic groups selected from O, NRa, NRa-C (O) Ra, NRa-C (O) ORa and NR-C (O) NR provided that (i) when R42 ** ** Formula is or then R43 ** ** Formula not be ** ** Formula or and (ii) when R43 is ** ** · Formula then R42 or will not be ** ** Formula

Term

Term ended

Expired 6 August 2024, 2.1 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

155 members in 31 offices

This recordMember, by publication datePriority claim21 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
49400803United States of AmericaP
57253404United States of AmericaP
2004025409United States of AmericaW

Members155

Family members, oldest first
DocumentOfficeKind
WO2005012294A1World Intellectual Property Organization (WIPO)A1
WO2005013996A2World Intellectual Property Organization (WIPO)A2
AU2004265288A1AustraliaA1
CA2533377A1CanadaA1
WO2005016893A2World Intellectual Property Organization (WIPO)A2
US2005113398A1United States of AmericaA1
WO2005013996A3World Intellectual Property Organization (WIPO)A3
WO2005016893A3World Intellectual Property Organization (WIPO)A3
WO2005063722A1World Intellectual Property Organization (WIPO)A1
US2005192301A1United States of AmericaA1
US2005209224A1United States of AmericaA1
US2005234049A1United States of AmericaA1
CA2566531A1CanadaA1
WO2005118544A2World Intellectual Property Organization (WIPO)A2
GB0523012D0United KingdomD0
WO2005012294A8World Intellectual Property Organization (WIPO)A8
US2006035891A1United States of AmericaA1
WO2005118544A3World Intellectual Property Organization (WIPO)A3
NO20060992LNorwayL
ITMI20052171A1ItalyA1
EP1656372A2European Patent Office (EPO)A2
FR2877944A1FranceA1
KR20060056353ARepublic of KoreaA
AU2005307849A1AustraliaA1
CA2580150A1CanadaA1
WO2006055561A2World Intellectual Property Organization (WIPO)A2
GB2420559AUnited KingdomA
EP1663242A2European Patent Office (EPO)A2
IL173299D0IsraelD0
DE102005054092A1GermanyA1
US2006167249A1United States of AmericaA1
EP1694652A1European Patent Office (EPO)A1
BRPI0413018ABrazilA
US7122542B2United States of AmericaB2
CN1849318AChinaA
HK1091209A1Hong Kong, ChinaA1
JP2007500722AJapanA
JP2007501793AJapanA
EP1763514A2European Patent Office (EPO)A2
JP2007514775AJapanA
NO20073068LNorwayL
IL181923D0IsraelD0
US2007167439A1United States of AmericaA1
US2007179140A1United States of AmericaA1
KR20070085571ARepublic of KoreaA
EP1824489A2European Patent Office (EPO)A2
RU2006106180ARussian FederationA
US2007225495A1United States of AmericaA1
MX2007005807AMexicoA
JP2007538092AJapanA
US2007299060A1United States of AmericaA1
US2008009484A1United States of AmericaA1
US2008009494A1United States of AmericaA1
US2008021020A1United States of AmericaA1
US2008027045A1United States of AmericaA1
US2008051412A1United States of AmericaA1
ES2296477A1SpainA1
CN101171012AChinaA
ZA200601460BSouth AfricaB
WO2006055561A3World Intellectual Property Organization (WIPO)A3
RS20060073ASerbiaA
JP2008520580AJapanA
GB2420559BUnited KingdomB
BRPI0516795ABrazilA
ZA200702180BSouth AfricaB
SG145698A1SingaporeA1
HK1114338A1Hong Kong, ChinaA1
US7452879B2United States of AmericaB2
US2008312438A1United States of AmericaA1
RU2007122381ARussian FederationA
US7511137B2United States of AmericaB2
RU2356901C2Russian FederationC2
US2009137589A1United States of AmericaA1
US2009176981A1United States of AmericaA1
US7560466B2United States of AmericaB2
US7582648B2United States of AmericaB2
UA88660C2UkraineC2
US2009318687A1United States of AmericaA1
NZ545270ANew ZealandA
UA91000C2UkraineC2
US7754714B2United States of AmericaB2
NZ554419ANew ZealandA
US7858633B2United States of AmericaB2
US7863286B2United States of AmericaB2
EP1824489B1European Patent Office (EPO)B1
US7868013B2United States of AmericaB2
AT494280TAustriaT
ATE494280T1AustriaT1
US7884111B2United States of AmericaB2
AU2011200367A1AustraliaA1
DE602005025803D1GermanyD1
RU2416604C2Russian FederationC2
DK1824489T3DenmarkT3
EP1663242B1European Patent Office (EPO)B1
AT506953TThis recordAustriaT
ATE506953T1AustriaT1
ES2359416T3SpainT3
SI1824489T1SloveniaT1
DE602004032446D1GermanyD1
US2011152518A1United States of AmericaA1
Showing 100 of 155